<DOC>
	<DOCNO>NCT00920101</DOCNO>
	<brief_summary>The purpose study determine whether HMG-CoA reductase inhibitor , atorvastatin attenuates inflammation atherosclerotic plaque detect 18F-fluorodeoxyglucose ( FDG ) PET .</brief_summary>
	<brief_title>Anti-inflammatory Effect Atorvastatin Atherosclerotic Plaques Assessed FDG-PET Imaging</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Plaque , Atherosclerotic</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Subjects accumulation FDGPET carotid artery aorta LDL cholesterol level ( calculate use Friedewald formula ) high 180 mg/dl less 120 mg/dl subject currently take HMG CoAreductase ( Statins ) fibrates symptomatic coronary artery diseases symptomatic cerebrovascular disease subject suffer myocardial infarction stroke within 6 month subject underwent percutaneous vascular intervention vascular operation within 6 month diabetic patient poor glycemic control ( HbA1c &gt; 8.5 ) hypertensive patient poor blood pressure control subject neoplasms subject systemic inflammatory disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>atherosclerotic plaque</keyword>
	<keyword>hypercholesterolemia</keyword>
	<keyword>HMG-CoA reductase inhibitor</keyword>
	<keyword>statin</keyword>
	<keyword>lipid-lowering therapy</keyword>
</DOC>